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A polymorphism in the fibroblast growth factor receptor 4 gene has been associated with cancer progression
and treatment resistance and is now reported to increase insulin secretion, providing a possible genetic link
between hyperinsulinemia and cancer (Ezzat et al., 2013).The increased cancer risk and cancer-
related mortality associated with condi-
tions such as metabolic syndrome,
obesity, and type 2 diabetes (T2D) has
now been well established through the
results of large cohort studies in many
different populations (Campbell et al.,
2012, Calle et al., 2003). While these
epidemiological studies provide evidence
of an association between these condi-
tions, the biological factors that promote
cancer growth in the setting of these
metabolic disorders remain to be deter-
mined. Identifying these factors will
potentially uncover therapeutic targets
for the treatment of cancer in these indi-
viduals. Human and preclinical studies
have thus far suggested that factors that
are altered in obesity and T2D, such as
hyperglycemia, hyperinsulinemia, hyper-
lipidemia, insulin-like growth factors
(IGFs), adipokines, and inflammatory
cytokines, may be etiological factors in
increasing cancer growth (Gallagher and
LeRoith 2011). Of these factors, endoge-
nous hyperinsulinemia has been high-
lighted by clinical and preclinical models
as an important factor in increasing
cancer growth. In womenwith breast can-
cer, in the absence of diabetes, hyperin-
sulinemia was found to be associated
with decreased recurrence-free survival
(Goodwin et al., 2002). Additionally,
increased expression of the insulin recep-
tor (IR) and the mitogenic form (IR-A)
and increased phosphorylation of the IR/
IGF-1 receptor (IGF-1R) has been re-
ported in breast samples from women
with decreased survival and resistance
to hormone therapy (Harrington et al.,
2012). In a mouse model of hyperinsuline-808 Cell Metabolism 17, June 4, 2013 ª2013mia, breast tumors induced by various
oncogenes grew more aggressively and
increased metastases; both measures
were inhibited by blocking the IR/IGF-1R
tyrosine kinase activity or by reducing
circulating insulin levels (Novosyadlyy
et al., 2010). In this issue of Cell Meta-
bolism, Ezzat et al. (2013) investigate the
connection between insulin and cancer
growth by examining the effect of the can-
cer-related polymorphism in the fibroblast
growth factor receptor 4 gene (FGFR4-
G388R) on insulin secretion.
The FGF family of growth factors and
receptors has many known components,
including 5 FGF receptors and 25 FGFs
in humans and mice (Itoh and Ornitz,
2004). Interestingly, a single nucleotide
polymorphism in the FGFR4 gene (glycine
to arginine in codon 388 in the transmem-
brane domain; FGFR4-G388R) is associ-
ated with breast cancer risk, progression,
and resistance to therapy (Xu et al., 2010,
2011). As the pancreatic islet cells nor-
mally express FGFR4 and its coreceptor
b-klotho, Ezzat et al. (2013) introduced
the FGFR4-G388R mutation into pancre-
atic RINm5F cells and showed that,
compared to wild-type cells, the FGFR4-
G388R-expressing cells secreted almost
twice as much insulin (Ezzat et al., 2013).
Following an in-depth study of the
signaling pathways involved, they found
that FGFR4-R388 cells failed to respond
normally to FGF stimulation, with no
measurable activation of FRS2, the prox-
imal substrate for the FGFRs. Microarray
analysis revealed increased expression
of the adaptor protein Grb14 in FGFR4-
R388 cells, which was mediated by the
activation of Stat3 and Stat5. In turn,Elsevier Inc.using small interfering RNA (siRNA)
to reduce Grb14 levels, Ezzat et al.
(2013) demonstrated that Grb14 is
responsible for the enhanced glucose-
stimulated insulin secretion by preventing
insulin-induced negative feedback via IR
activation.
The study then progressed to a genetic
knockin of the FGFR4-R385 mutation
(mouse homolog to FGFR4-R388). Ezzat
et al. (2013) found that in these mice
Grb14 expression in b cells was
increased, and the mice demonstrated
modest improvements in glucose toler-
ance and increased insulin secretion
without any change in insulin sensitivity,
suggesting that the pancreatic effects
were not secondary to any peripheral
metabolic changes. These effects were
abrogated when the FGFR4-R385 mice
were crossed with Grb14/ mice, there-
fore confirming that the positive effect of
Grb14 on insulin secretion was conserved
in vivo. Most importantly, having applied
the results to a number of different popu-
lations, the FGFR4-G388R polymorphic
allele was associated with lower blood
glucose levels in some studies and a pro-
tection against the development of T2D in
prediabetic individuals. Some studies re-
ported a reduction in glucose in individ-
uals with the FGFR4-G388R allele, along
with improved insulin resistance, while
no change in insulin resistance was found
in other populations.
The study by Ezzat et al. (2013) raises a
number of interesting and important
questions that should lead to further
experimentation. First, since the FGFR4-
G388R polymorphic allele is associated
with increased cancer risk and prognosis,
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answered is whether the effect on b cell
insulin secretion plays any role in this
effect, given that hyperinsulinemia is a
potential causal factor in cancer growth
and metastases. Any effect of insulin on
tumor growth would most likely require
chronic hyperinsulinemia, and this would
be associated with insulin resistance.
The FGFR4-R385 knockin mice demon-
strated increased insulin secretion in
response to glucose, but no change in
insulin sensitivity. Thus, whether the
increased risk of cancer with the
FGFR4-R388 polymorphism is due to
increased insulin secretion remains to
be determined, as this polymorphism
seems to be protective against diabetes.
The FGFR receptor isoforms have diver-
gent signaling properties in different
tissues; therefore, the FGFR4-R388 poly-
morphism may have other signaling
effects in the tumor tissue, possibly
directly increasing IR signaling in tumor
cells, as seen in b cells in vitro. Similarly,
this polymorphism was shown to affect
b cells in the mouse model. Unless the
polymorphism also affected additional
peripheral metabolic tissues, such as
muscle and adipocytes, how would this
explain the improved insulin sensitivity insome of the human studies? Another
unanswered question is how the single
nucleotide polymorphism actually affects
the function of the FGFR4 receptor. While
alterations in amino acid sequences have
been shown to inhibit or enhance recep-
tor function via alterations in substrate
binding and activation, this was not un-
dertaken in the present study. These
types of studies will certainly help both
in understanding the underlying patho-
physiology and in the consideration of
potential drug targets.
The exciting results from Ezzat et al.
(2013) demonstrate the application of
cell culture and mouse models to deter-
mine the mechanisms through which
polymorphisms identified in human
population studies can lead to disease.
This study completes the circle by return-
ing to human studies to examine whether
the in vitro and animal findings are
applicable to human populations and
also raises many questions for future
investigation.REFERENCES
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The mechanisms underlying the biological activity of metformin, a widely prescribed drug to treat type 2
diabetes, remain elusive. In a recent issue ofCell,Cabreiro et al. report that inC. elegans,metformin indirectly
impacts lifespan by altering the methionine metabolism of its microbial partner E. coli (Cabreiro et al., 2013).Metformin is a widely prescribed oral
antihyperglycemic agent of the biguanide
family recommended as first-line therapy
for type 2 diabetes. One generally
accepted mechanism for metformin ac-
tion is a mild and transient inhibition of
hepatocyte mitochondrial respiratory-
chain complex-1, which restricts thehepatic gluconeogenic program (Viollet
and Foretz, 2013). Despite its prom-
inence on the antidiabetic drug market,
the exact mechanism of metformin action
has not been fully elucidated. Its impact
on hepatic gluconeogenesis has been
linked to the decrease of cellular energy
status, which activates the cellularmetabolic sensor AMP-activated protein
kinase (AMPK). Recent studies have,
however, challenged this view, revealing
the importance of other AMPK-indepen-
dent mechanisms (Miller et al., 2013).
Metformin biological activity goes beyond
its current therapeutic usage as it has
been also shown to reduce the risk of17, June 4, 2013 ª2013 Elsevier Inc. 809
